Marker Test Diagnostics to Discuss Groundbreaking Drug Testing Marker During AACC Annual Conference

Marker Test Diagnostics, an international supplier to the drug testing industry, announced today that representatives from the company will attend the 2014 American Association for Clinical Chemistry (AACC) Annual Meeting July 27 – 31 at McCormick Place in Chicago, IL. The company will attend the conference to promote the development and U.S. expansion for UR Code™, an oral marker developed by Marker Test that “bar-codes” a subject’s urine and eliminates the need to supervise urine collection.

In the form of a soft gel capsule, UR Code provides an accurate, secure and cost-effective answer to common drug testing challenges by:

• Inhibiting manipulations
• Eliminating false negative results
• Ensuring sample integrity
• Protecting the privacy of the test subject

Already well-known and trusted in Germany, UR Code is poised for an explosive entry into the U.S. market. Marker Test Diagnostics’ CEO Kim Christensen and President Caroline Bussenius will be available to discuss the history and future plans for the revolutionary marker.

Immediately following the conference on August 1, Marker Test will distribute a Request for Proposals (RFP) to laboratories that responded to an earlier RFI to compete for consideration for “exclusivity” to market and sell the UR Code product in the United States.

For more details about the AACC Conference or to make an appointment to meet with representatives from Marker Test, contact info@markertest.com.

About Marker Test Diagnostics

Founded in 2013, Marker Test Diagnostics is the producer of UR Code (TM), an innovative oral marker for the drug testing market. Marker Test Diagnostics is currently conducting research studies in the field of addiction and sport and collaborates with the Olympic Doping Laboratory at the UCLA and a renowned research university. For more information about Marker Test Diagnostics, visit www.markertest.com.